VIC-1911 clinical trials
VIC-1911 is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Shanghai Jiao Tong University School of Medicine (1). The most-studied condition is GVHD (Acute or Chronic).
Patient leaflets for VIC-1911
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of VIC-1911
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children
NCT07350057 · ClinicalTrials.gov ↗ · GVHD (Acute or Chronic)
|
Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | China |
|
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
NCT06519721 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Not applicable | Active, closed | RenJi Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with VIC-1911
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Shanghai Jiao Tong University School of Medicine | 1 |
| RenJi Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about VIC-1911 trials
How many clinical trials are testing VIC-1911?
2 current trials in our China register name VIC-1911 as a drug or biological intervention, as of the registry sync on 21 October 2026. Completed and withdrawn studies are not counted.
Are VIC-1911 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors VIC-1911 clinical trials?
Shanghai Jiao Tong University School of Medicine (1) and RenJi Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how VIC-1911 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how VIC-1911 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists VIC-1911 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 21 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.